Literature DB >> 15250049

Chondrogenic differentiation of mesenchymal stem cells and its clinical applications.

Jin Woo Lee1, Yun Hee Kim, Su-Hyang Kim, Seung Hwan Han, Soo Bong Hahn.   

Abstract

Tissue engineering has the potential to provide cartilaginous constructs capable of restoring the normal function of native articular cartilage following joint injury or degradation. One approach to functional tissue engineering of cartilage involves the in vitro cultivation of tissue constructs by using: (i) chondrogenic cells that can be selected, expanded, and transfected to overexpress the genes of interest, (ii) scaffolds that provide a defined three-dimensional structure for tissue development and biodegrade at a controlled rate. Understanding the functional potential of the cells and the signaling mechanisms underlying their differentiation should lead to innovative protocols for clinical orthopaedic interventions. A large number of growth factors and hormones have been implicated in the regulation of chondrocyte biology, relatively little is known about the intracellular signaling pathways involved. We have tried to define the roles of specific TGF- dependent signaling pathways involved in the regulation of chondrogenesis from human mesenchymal stem cells. Chondrogenesis induced by TGF-beta3 in alginate bead system was confirmed by examining cartilage specific type II collagen expression and aggrecan, whereas type I collagen expression was not affected by TGF-beta3. Type II collagen mRNA expression was expressed strongly during chondrogenesis and MEK inhibition (U0126) resulted in complete down-regulation of type II collagen. In contrast, aggrecan expression was detected in same level by treatment of U0126. These results strongly suggest that the ERK signaling cascade is involved in TGF-beta3 induced-chondrogenesis signaling pathways and a role of its pathway is necessary over a longer period to promote type II collagen expression. However, their end product properties in vivo have not been well known. In this study, an articular cartilage from chondrogenic MSCs with PLGA scaffolds (75:25 and 65:35) were made and analyzed its biochemical, histological and mechanical properties in vitro and in vivo. And also, we evaluated the cartilage formation in vivo through the injection of cell-thermosensitive gel complex, a newly developed injectable material. At 12 weeks after PLGA scaffolds containing chondrogenic MSCs transplantation, the separated rabbit distal femur showed a good gross articular cartilage appearance in the transplanted site. In indentation test, compare to the native articular cartilage, the engineered cartilage from two types of (75:25 and 65:35) achieved up to 30-60% in mechanical stiffness. And also, a new model for cartilage formation in bladder, at 14 weeks after injection, we could find out mass formation in the submucosal area grossly. H&E staining, alcian blue staining and other special staining confirmed the chondrogenic differentiation in the mass. These cell therapy technologies can provide the possibility of clinical applications for vesicoureteral reflux and reflux esophagitis, and urinary incontinence as well as articular cartilage regeneration.

Entities:  

Mesh:

Year:  2004        PMID: 15250049     DOI: 10.3349/ymj.2004.45.Suppl.41

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  21 in total

1.  Chondrogenesis from umbilical cord blood cells stimulated with BMP-2 and BMP-6.

Authors:  Cristiane Sampaio de Mara; A S S Duarte; A R Sartori-Cintra; A C M Luzo; S T O Saad; I B Coimbra
Journal:  Rheumatol Int       Date:  2012-01-12       Impact factor: 2.631

2.  Comparison of biological characteristics of marrow mesenchymal stem cells in hepatitis B patients and normal adults.

Authors:  Liang Peng; Hua Li; Lin Gu; Xiao-Mou Peng; Yang-Su Huang; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2007-03-21       Impact factor: 5.742

3.  Study of differential effects of TGF-beta3/BMP2 on chondrogenesis in MSC cells by gene microarray data analysis.

Authors:  Yunxia Sang; Weidong Zang; Yan Yan; Yong Liu; Qiang Fu; Kang Wang; Yantian Chen; Nianmin Qi
Journal:  Mol Cell Biochem       Date:  2013-11-07       Impact factor: 3.396

4.  MEK/ERK and p38 MAPK regulate chondrogenesis of rat bone marrow mesenchymal stem cells through delicate interaction with TGF-beta1/Smads pathway.

Authors:  J Li; Z Zhao; J Liu; N Huang; D Long; J Wang; X Li; Y Liu
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

5.  Bone marrow-derived mesenchymal stem cells versus bone marrow nucleated cells in the treatment of chondral defects.

Authors:  Yi Zhang; Fuyou Wang; Jiarong Chen; Zhigang Ning; Liu Yang
Journal:  Int Orthop       Date:  2011-10-28       Impact factor: 3.075

Review 6.  Bioreactors to influence stem cell fate: augmentation of mesenchymal stem cell signaling pathways via dynamic culture systems.

Authors:  Andrew B Yeatts; Daniel T Choquette; John P Fisher
Journal:  Biochim Biophys Acta       Date:  2012-06-15

7.  Ex vivo expansion and pluripotential differentiation of cryopreserved human bone marrow mesenchymal stem cells.

Authors:  Ying Xiang; Qiang Zheng; Bing-bing Jia; Guo-ping Huang; Yu-lin Xu; Jin-fu Wang; Zhi-jun Pan
Journal:  J Zhejiang Univ Sci B       Date:  2007-02       Impact factor: 3.066

8.  An adhesive bone marrow scaffold and bone morphogenetic-2 protein carrier for cartilage tissue engineering.

Authors:  Jacob A Simson; Iossif A Strehin; Qiaozhi Lu; Manuel O Uy; Jennifer H Elisseeff
Journal:  Biomacromolecules       Date:  2013-02-04       Impact factor: 6.988

9.  Comparison of proliferative and multilineage differentiation potentials of cord matrix, cord blood, and bone marrow mesenchymal stem cells.

Authors:  Prathibha Shetty; Khushnuma Cooper; Chandra Viswanathan
Journal:  Asian J Transfus Sci       Date:  2010-01

Review 10.  Stimulation of chondrogenic differentiation of mesenchymal stem cells.

Authors:  Da-Ae Yu; Jin Han; Byung-Soo Kim
Journal:  Int J Stem Cells       Date:  2012-05       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.